Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Goldenwell Biotech (GWLL) Debt to Equity (2023 - 2025)

Goldenwell Biotech filings provide 3 years of Debt to Equity readings, the most recent being -$1.17 for Q1 2025.

  • On a quarterly basis, Debt to Equity changed N/A to -$1.17 in Q1 2025 year-over-year; TTM through Mar 2025 was -$1.17, a N/A change, with the full-year FY2024 number at -$2.02, down 326.79% from a year prior.
  • Debt to Equity hit -$1.17 in Q1 2025 for Goldenwell Biotech, up from -$2.02 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $0.89 in Q4 2023 to a low of -$2.02 in Q4 2024.
  • Median Debt to Equity over the past 3 years was -$1.17 (2025), compared with a mean of -$0.77.
  • The widest YoY moves for Debt to Equity: up 326.79% in 2024, down 326.79% in 2024.
  • Goldenwell Biotech's Debt to Equity stood at $0.89 in 2023, then plummeted by 326.79% to -$2.02 in 2024, then skyrocketed by 42.12% to -$1.17 in 2025.
  • The last three reported values for Debt to Equity were -$1.17 (Q1 2025), -$2.02 (Q4 2024), and $0.89 (Q4 2023) per Business Quant data.